Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design. Iktos develops a proprietary and innovative solution based on generative deep learning models, which allows, from existing data, to design optimized molecules in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, MakyaTM. Iktos also develops SpayaTM, a synthesis planning software based on Iktos' proprietary AI technology for retrosynthesis. Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB...